Dabrafenib and/or Trametinib Rollover Study
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
What the trial team says
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
Key facts
- Registry number
- NCT03340506
- Stage of testing
- Phase 4
- Conditions studied
- Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma
Where it is running
This trial lists 33 sites.
-
Arizona
- Honor Health Research Institute (Scottsdale)
-
Baden-Wurttemberg
- Novartis Investigative Site (Mannheim)
-
Buenos Aires
- Novartis Investigative Site (Caba)
-
Chiba
- Novartis Investigative Site (Kashiwa)
-
China
- Novartis Investigative Site (Beijing)
-
Denmark
- Novartis Investigative Site (Copenhagen)
-
France
- Novartis Investigative Site (Lyon)
- Novartis Investigative Site (Nantes)
- Novartis Investigative Site (Paris)
- Novartis Investigative Site (Paris)
- Novartis Investigative Site (Villejuif)
-
Germany
- Novartis Investigative Site (Augsburg)
- Novartis Investigative Site (Berlin)
- Novartis Investigative Site (Essen)
- Novartis Investigative Site (Hamburg)
- Novartis Investigative Site (Hamburg)
- Novartis Investigative Site (Heidelberg)
-
Hajdu Bihar Megye
- Novartis Investigative Site (Debrecen)
-
Hat Yai
- Novartis Investigative Site (Songkhla)
-
Hungary
- Novartis Investigative Site (Budapest)
-
Maryland
- National Institute Of Health (Bethesda)
-
Netherlands
- Novartis Investigative Site (Utrecht)
-
Ohio
- James Cancer Hospital and Solove Research Institute Ohio State (Columbus)
-
South Holland
- Novartis Investigative Site (Rotterdam)
-
Spain
- Novartis Investigative Site (Barcelona)
- Novartis Investigative Site (Madrid)
- Novartis Investigative Site (Madrid)
- Novartis Investigative Site (Madrid)
- Novartis Investigative Site (Madrid)
- Novartis Investigative Site (Valencia)
-
Texas
- Mary Crowley Cancer Research (Dallas)
-
Tokyo
- Novartis Investigative Site (Chuo Ku)
-
Tyrol
- Novartis Investigative Site (Innsbruck)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.